ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Oct 14, 2016
Where I Went Wrong on Gilead
Image Source: torbakhopper. Let’s walk through our run-in with Gilead.
Oct 13, 2016
Understanding the Chartered Financial Analyst (CFA) Designation
Let's examine why the Economist (magazine) calls the CFA the gold standard in the investment industry.
Sep 12, 2016
The Quiet Analyst Speaks
Image: Mailslot for Cantor Fitzgerald, on the top floors of the WTC. The mailslot was located in a post office near the WTC site. The mailslots are with the Smithsonian Institution. Travis Wise. Let's get caught up...
Jul 19, 2016
The J&J-Gilead Trade-off Update
Some of our members were not happy when we swapped out Gilead and replaced it with Johnson & Johnson in the portfolio of the Best Ideas Newsletter. How have things progressed since that trade late January?
Jun 27, 2016
Keep Calm and Carry On?
Image Source: War History Online, June 22. Markets often overshoot to the downside, and we’re not even at “fair valuation” in the context of widely-followed market multiples. Patience is a virtue.
Jun 15, 2016
5 Years Strong!
Image Source: Andy Maguire. So much to say... let's talk.
May 3, 2016
Dividend Increases/Decreases for the Week Ending April 29
Let's take a look at companies raising/lowering their dividends this week.
May 2, 2016
Gilead: What's Your Long Term Thesis?
Image Source: Gilead. We’re starting to see some even bigger risks at Gilead – long-term ones.
Apr 29, 2016
Gilead Disappoints, Harvoni Sales Drop 16%
Image Source: Gilead. In January 2016, we had removed Gilead from the Best Ideas Newsletter portfolio, and we added steady-eddy dividend growth giant Johnson & Johnson in its place. We were starting to think we might have made a mistake … until today.
Apr 19, 2016
Domestic Pharma Drives JNJ's 1Q; Stock Hits All-Time High
Johnson & Johnson reported strong growth in its Pharmaceutical segment in the first quarter of 2016. The underlying strength allowed the firm to raise its full-year forecasts after adjusting its outlook on currency expectations for the year.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.